NASDAQ:ATXI Avenue Therapeutics 5/15/2024 Earnings Report $0.22 -0.02 (-9.96%) As of 09:45 AM Eastern ProfileEarnings History Avenue Therapeutics EPS ResultsActual EPS-$15.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAvenue Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAvenue Therapeutics Announcement DetailsQuarterDate5/15/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsAvenue Therapeutics' next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Avenue Therapeutics Earnings HeadlinesAvenue Living Completes $250 Million Inaugural Senior Unsecured Notes OfferingMay 12, 2025 | finance.yahoo.comEaster on Parade will hop back to Monument Avenue for annual celebrationApril 18, 2025 | msn.comTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.May 30, 2025 | Paradigm Press (Ad)Crash on Parnell Avenue forces detour near St. Joseph RiverApril 18, 2025 | msn.comWest Asheville's Patton Avenue is getting a section of new sidewalk: What to knowApril 18, 2025 | usatoday.comRest of Lombardi Avenue, from Military to Holmgren Way, to close April 19 for 2025 NFL DraftApril 18, 2025 | msn.comSee More Avenue Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avenue Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avenue Therapeutics and other key companies, straight to your email. Email Address About Avenue TherapeuticsAvenue Therapeutics (NASDAQ:ATXI), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.View Avenue Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the Stock Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
